论文部分内容阅读
目的探讨替米沙坦对2型糖尿病合并高血压患者血脂及胰岛素抵抗的影响。方法将84例2型糖尿病合并高血压患者分为两组各42例,均口服药物控制血糖,降压药物对照组给予氯沙坦钾,观察组给予替米沙坦,2个疗程后对比两组血压、胰岛素抵抗指数(IRI)及甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)等血脂指标、血清水平的变化情况。结果两组治疗前后血压、IRI均明显下降,但观察组下降更为显著,观察组TG、LDL-C较前治疗明显降低,差异有统计学意义(P<0.05);对照组治疗前后TG、LDL-C无明显改变(P>0.05)。结论替米沙坦良好控制2型糖尿病合并高血压患者血压的同时可降低胰岛素抵抗,改善血脂代谢,可作为本病首选药物应用。
Objective To investigate the effect of telmisartan on blood lipid and insulin resistance in type 2 diabetic patients with hypertension. Methods Eighty-four patients with type 2 diabetes mellitus and hypertension were divided into two groups of 42 patients. All patients were given oral medication to control blood sugar. Losartan control group was given losartan potassium, and telmisartan was given to the observation group. After two courses of treatment, Blood pressure, insulin resistance index (IRI) and triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and other lipid indicators, serum levels changes. Results Before and after treatment, the blood pressure and IRI decreased obviously in both groups, but the decrease in the observation group was more significant. The TG and LDL-C in the observation group were significantly lower than those before treatment (P <0.05) LDL-C had no significant change (P> 0.05). Conclusion Telmisartan can control the blood pressure of patients with type 2 diabetes mellitus and hypertension, reduce insulin resistance and improve blood lipid metabolism, which can be used as the drug of choice for this disease.